Safety and Tolerability of Antipsychotic Treatment in Young Patients With Schizophrenia
J Clin Psychiatry 2011;72(8):e26
© Copyright 2015 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Antipsychotics have proven efficacy for treating patients with early-onset schizophrenia, and aripiprazole, olanzapine, quetiapine, and risperidone have FDA approval for treating adolescents aged 13 to 17 years. Children and adolescents appear to have a higher risk than adults for experiencing adverse events such as extrapyramidal symptoms, prolactin elevation, weight gain, and metabolic effects when taking antipsychotic medications. Pediatric studies indicate that adverse effect profiles differ among commonly used antipsychotics. Clinicians should consider the differing adverse effect profiles when choosing medications for young patients.
See the entire activity.